{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-024880","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.200093+00:00","generated_at":"2026-06-24T21:55:24.554525+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LENSAR holds commercial launch meeting for ALLY System after FDA clearance","bullets":["LENSAR (LNSR) held commercial launch meeting week of June 27, 2022 for ALLY Adaptive Cataract Treatment System.","Company expects to place 8 to 12 ALLY Systems in a controlled initial launch starting Q3 2022.","ALLY launched with phacoemulsification features disabled; second 510(k) delayed due to predicate device withdrawal.","Supply chain constraints delayed raw material delivery; wider U.S. availability planned for 2023.","LENSAR plans to file CE Mark application in 2022 to commercialize ALLY in the European Union."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-024880","json":"https://secwatch.observer/filing/0001564590-22-024880.json","markdown":"https://secwatch.observer/filing/0001564590-22-024880.md","text":"https://secwatch.observer/filing/0001564590-22-024880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022024880/0001564590-22-024880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022024880/lnsr-8k_20220627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:55:24.554525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}